Fostair (Asthma) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 53 Pages
|Fostair(氣喘):市場預測與分析 Fostair (Asthma) - Forecast and Market Analysis to 2023|
|出版日期: 2014年08月31日||內容資訊: 英文 53 Pages||
Fostair是Chiesi所開發，是二丙酸氯地米松這種ICS跟富馬酸福莫特羅這種LABA的FDC(固定劑量複方藥物)。二丙酸氯地米松是可代謝二種活性代謝物的前驅藥(prodrug)。17-monopropionate metabolite具有2117-monopropionate metabolite30倍的親和性，可阻礙氣喘媒介物質的分泌。二丙酸氯地米松被Teva以QVAR之名推出上市。同時富馬酸福莫特羅是高度選擇性的LABA(長效型β2刺激藥)，可提升AMP水準來緩和氣管平滑肌的緊張狀態，抑制由肺釋出的肥胖細胞媒介物(組織胺、白三烯、前列腺素D2等)。AstraZeneca將福莫特羅以「Oxis Turbuhaler」這個名稱作為獨立藥品推出上市，此外其他公司(Novartis等)也有製造福莫特羅上市。
GlobalData has released its new PharmaPoint Drug Evaluation report, "Fostair (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Fostair, developed by Chiesi, is an FDC of the ICS beclomethasone dipropionate and the LABA formoterol fumarate. Beclomethasone dipropionate is a prodrug that is metabolized to two active metabolites. The 17-monopropionate metabolite has a 30-fold greater affinity for glucocorticoid receptors than its 21-monopropionate counterpart and inhibits the secretion of mediators involved in asthma. Beclomethasone dipropionate is marketed as a standalone product, Teva's QVAR. Formoterol fumarate is a highly selective LABA. It acts by increasing cAMP, which, in turn, leads to relaxation of the bronchial smooth muscle. This way, formoterol inhibits the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from the human lung. AstraZeneca markets formoterol as a standalone drug under the name of Oxis Turbuhaler. Other companies also market formoterol, one example being Novartis' Foradil.